孟鲁斯特联合黄芪颗粒在儿童咳嗽变异性哮喘中的疗效观察被引量：2

Therapeutic efficacy of montelukast and astragalus on children coμgh variant asthma

下载PDF

导出

摘要目的:研究孟鲁斯特联合黄芪颗粒在儿童咳嗽变异性哮喘(CVA)治疗中的临床疗效。方法:选择确诊为CVA的100例患儿为观察对象,随机分为对照组与治疗组,每组50例,对照组给予丙卡特罗口服及普米克令舒雾化治疗,治疗组在对照组基础上加用孟鲁斯特及黄芪颗粒治疗,比较两组疗效。结果:治疗组疗效显著高于对照组(P<0.05)。结论:孟鲁斯特联合黄芪颗粒在儿童咳嗽变异性哮喘治疗中的临床疗效显著。 Objective To assess the efficacy of montelukast and astragalus on children variant asthma.Methods 100 children with CVA were randomly divided into two groups,objective group（n=50） and control group（n=50）.The children of control group took Procaterol and inhaled Pulmicont,while those of objective group additionally took montelukast and astragalus,assess the efficacy of two groups.Results The effective of objective group was higher than that of the control group（P〈0.05）.Conclusion The montelukast and astragalus are effective for CVA.

作者李琴

机构地区广东省阳江市妇幼保健院儿科

出处《吉林医学》 CAS 2013年第21期4214-4215,共2页 Jilin Medical Journal

关键词孟鲁斯特黄芪咳嗽变异性哮喘儿童 Montelukast Astragalus Cough variant asthma Children

分类号 R725.6 [医药卫生—儿科]

引文网络
相关文献

参考文献5

1中华医学会儿科学分会呼吸学组.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志,2004,42(2):100-106. 被引量：2631
2中华医学会儿科学分会呼吸学组.儿童支气管哮喘诊断与防治指南.中华儿科杂志,2008,.
3朱元钰,陈文彬.呼吸病学[M].北京:人民卫生出版社,2004:1014
4彭秋莹,陈爱欢.白三烯研究进展及其在婴幼儿喘息性疾病中的作用[J].中华儿科杂志,2006,44(7):553-556. 被引量：94
5鲍仁孝,李峻极,赵淑媛.胸腺肽、黄芪防治毛细支气管炎疗效观察[J].实用儿科临床杂志,1996,11(1):42-43. 被引量：16

二级参考文献30

1Jae-Won OH,Shin Su-A,Ha-Baik Lee.Urine leukotriene E4 and eosinophil cationic protein in nasopharyngeal aspiration from young wheezy children.Pediatr Allergy Immunol,2005,16:416-421.
2Dimova-Yaneva D,Russell D,Main M,et al.Eosinphil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis.Clin Exp Allergy,2004,34:555-558.
3Tanaka S,Tanaka H,Abe S.High Dose of Inhaled Fluticasone Reduces High Levels of Urinary Leukotriene E4 in the Early Morning in Mild and Moderate Nocturnal Asthma.Chest,2003,124:1768-1773.
4Mitsuta K,Shimoda T,Fukushima C,et al.Preoperative steroid therapy inhibits cytokine production in the lung parenchyma in asthmatic patients Chest,2001,120:1175-1183.
5O'Shaughnessy KM,Wellings R,Gillies B,et al.Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion.Am Rev Respir Dis,1993,147:1472-1476.
6Vachier I,Kumlin M,Dahlen SE,et al.High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma.Respir Med,2003,97:1225-1229.
7Pavord ID,Ward R,Woltmann G,et al.Induced sputum eicosanoid concentrations in asthma.Am J Respir Crit Care Med,1999,160:1905 -1909.
8Busse W,Raphael GD,Galant S,et al.Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma:a randomized clinical trial.J Allergy Clin Immunol,2001,107:461-468.
9Meltzer EO,Lockey RF,Friedman BF,et al.Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma.Mayo Clin Proc,2002,77:437-445.
10Bukstein DA,Luskin AT,Bernstein A."Real-world" effectiveness of daily controller medicine in children with mild persistent asthma.Ann Allergy Asthma Immunol,2003,90:543-549.